Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial.

Diabetes Metab J · 2024 · PMC11449827 · PMID 38650099

Europe PMC DOI

hedged sentence

0.0595

closest p · 1.2× alpha

0.0595

boldest claim

The sentences

did not reach statistical significanceP =0.0595so close (0.05 < p ≤ 0.1)

Additionally, patients who failed on pioglitazone monotherapy had a lower BMI (25.43±3.28 kg/m2) compared to those who achieved the target glycemic level (27.17±3.06 kg/m2), although this difference did not reach statistical significance ( P =0.0595).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.